Drugs for Hepatitis C: Demand is Falling
Thanks to high effectiveness of hepatitis C treatment using new methods, the number of patients suffering from this disease is falling.
It also means that fewer drugs are required. Having analyzed the US and European data, as well as evidence from Japan, Brazil and China, the experts forecast the market volume downfall by 2.1% annually. It implies, that by 2025 the global market of drugs against viral hepatitis C will fall by approximately 4 bln dollars and will be worth US$17.5 bln.
But it does not mean that the drugs will cease to be manufactured. Unfortunately, epidemics sometimes come back. For the sake of the national security supplies of drugs against all diseases must be available.